HOLX:NSD-Hologic, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 72.36

Change

-2.79 (-3.71)%

Market Cap

USD 19.36B

Volume

2.24M

Average Target Price

USD 89.46 (+23.63%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

-16.92 (-2.23%)

USD89.31B 86.02 62.70
NVCR NovoCure Limited

-24.23 (-14.00%)

USD17.62B 940.92 572.74
MASI Masimo Corporation

-5.09 (-2.03%)

USD13.83B 60.68 45.25
XRAY DENTSPLY SIRONA Inc

-1.57 (-2.91%)

USD11.80B 126.19 41.22
RGEN Repligen Corporation

-8.51 (-3.95%)

USD11.80B 261.31 139.97
STAA STAAR Surgical Company

-8.57 (-7.46%)

USD5.35B 607.72 565.38
ICUI ICU Medical, Inc

-1.35 (-0.61%)

USD4.61B 58.08 22.68
IRTC iRhythm Technologies, Inc

-5.27 (-3.44%)

USD4.42B N/A N/A
MMSI Merit Medical Systems, Inc

-1.61 (-2.85%)

USD3.11B 379.20 44.75
ATRC AtriCure, Inc

+2.37 (+3.80%)

USD2.81B N/A N/A

ETFs Containing HOLX

Symbol Name Weight Mer Price(Change) Market Cap
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

-1.24 (-1.67%)

USD0.51B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.65% 32% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.65% 32% F 22% F
Trailing 12 Months  
Capital Gain 51.73% 61% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.73% 61% D- 65% D
Trailing 5 Years  
Capital Gain 106.27% 46% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.27% 46% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 13.99% 32% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.99% 32% F 67% D+
Risk Return Profile  
Volatility (Standard Deviation) 17.29% 97% A+ 74% C
Risk Adjusted Return 80.90% 74% C 88% B+
Market Capitalization 19.36B 97% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.27 87% B+ 63% D
Price/Book Ratio 5.97 45% F 32% F
Price / Cash Flow Ratio 21.60 55% F 20% F
EV/EBITDA 9.63 95% A 73% C
Management Effectiveness  
Return on Equity 49.87% 100% A+ 98% A+
Return on Invested Capital 22.24% 93% A 93% A
Return on Assets 17.07% 100% A+ 98% A+
Debt to Equity Ratio 100.32% 7% F 23% F
Technical Ratios  
Short Ratio 2.33 58% F 50% F
Short Percent 2.73% 55% F 55% F
Beta 1.22 48% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector